Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Phase 2
Completed
- Conditions
- Thyroid Cancer
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT00121628
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 446
- Registration Number
- NCT00121602
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
Phase 3
Completed
- Conditions
- InflammationPsoriasis
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT00121615
Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00121043
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- Gynecological MalignanciesGenital Neoplasms, FemaleAnemia
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00121030
REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- Amgen
- Registration Number
- NCT00121056
Treatment for Patients Suffering From Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- Breast CancerAnemia
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00120692
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Phase 2
Completed
- Conditions
- NeoplasmsAnemia
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 204
- Registration Number
- NCT00120705
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- Non-Small Cell Lung CancerAnemia
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00120679
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00119613
© Copyright 2025. All Rights Reserved by MedPath